Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher?
Treating rare diseases can't be profitable because there are too few patients, right? As it turns out, targeting uncommon and severe illnesses can be a brilliant business decision -- especially if it's possible to make a better drug product than the alternatives. And for companies with therapies that do outperform, capturing massive market share can occur quite quickly.
That's exactly the situation for the rare-disease drug developer BioCryst Pharmaceuticals (NASDAQ: BCRX). BioCryst isn't profitable yet, though with soaring revenue growth from its recently launched hereditary angioedema (HAE) drug called Orladeyo, that could soon change. Its stock has soared 126% in 2021 so far, and if its new drug rollout proceeds as planned, it will probably go even higher. The only challenge for investors is knowing when the catalysts will run out.
Image source: Getty Images.
Source Fool.com
